Aflatoxin B1-DNA adduct formation and mutagenicity in livers of neonatal male and female B6C3F1 mice

Toxicological Sciences

Volumn 122, Issue 1, 2011, Pages 38-44

  Woo, Leslie L ^a   Egner, Patricia A ^b   Belanger, Crystal L ^a   Wattanawaraporn, Roongtiwa ^a   Trudel, Laura J ^a   Croy, Robert G ^a   Groopman, John D ^b   Essigmann, John M ^a   Wogan, Gerald N ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Johns Hopkins University   (United States)

Author keywords

Aflatoxin; Gpt delta mouse; Hepatocarcinoma; Mutation; Neonatal mouse

Indexed keywords

AFLATOXIN B1; AFLATOXIN B1 DNA ADDUCT; AFLATOXIN B1-DNA ADDUCT; GUANINE; MUTAGENIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CARCINOGEN DNA INTERACTION; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DOSE RESPONSE; FEMALE; GENE MUTATION; GENOTOXICITY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; MOUSE STRAIN; MUTAGENICITY; MUTATION RATE; MUTATIONAL ANALYSIS; NEWBORN; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; SEQUENCE ANALYSIS; SEX DIFFERENCE; TRANSGENE; AGE; ANIMAL; C57BL MOUSE; CARCINOGEN TESTING; CHEMICALLY INDUCED DISORDER; DNA SEQUENCE; DRUG EFFECT; GENETICS; LIVER; LIVER TUMOR; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALIA; MUS;

AFLATOXIN B1; AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; BASE SEQUENCE; CARCINOGENICITY TESTS; CARCINOMA, HEPATOCELLULAR; DNA ADDUCTS; FEMALE; GUANINE; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTAGENS; MUTATION RATE; SEQUENCE ANALYSIS, DNA; SEX FACTORS;

EID: 79961010169     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr087     Document Type: Article

References (35)

1. Adams, W. T., and Skopek, T. R. (1987). Statistical test for the comparison of samples from mutational spectra. J. Mol. Biol. 194, 391-396.
2. Anderson, L. M., Diwan, B. A., Fear, N. T., and Roman, E. (2000). Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models. Environ. Health Perspect. 108(Suppl. 3), 573-594.
3. Bailey, E. A., Iyer, R. S., Stone, M. P., Harris, T. M., and Essigmann, J. M. (1996). Mutational properties of the primary aflatoxin B1-DNA adduct. Proc. Natl. Acad. Sci. U.S.A. 93, 1535-1539.
4. Benasutti, M., Ejadi, S., Whitlow, M. D., and Loechler, E. L. (1988). Mapping the binding site of aflatoxin B1 in DNA: systematic analysis of the reactivity of aflatoxin B1 with guanines in different DNA sequences. Biochemistry 27, 472-481.
5. Brown, K. L., Deng, J. Z., Iyer, R. S., Iyer, L. G., Voehler, M. W., Stone, M. P., Harris, C. M., and Harris, T. M. (2006). Unraveling the aflatoxin-FAPY conundrum: structural basis for differential replicative processing of isomeric forms of the formamidopyrimidine-type DNA adduct of aflatoxin B1. J. Am. Chem. Soc. 128, 15188-15199.
6. Cariello, N. F., Piegorsch, W. W., Adams, W. T., and Skopek, T. R. (1994). Computer program for the analysis of mutational spectra: application to p53 mutations. Carcinogenesis 15, 2281-2285.
7. Chen, T., Heflich, R. H., Moore, M. M., and Mei, N. (2010). Differential mutagenicity of aflatoxin B1 in the liver of neonatal and adult mice. Environ. Mol. Mutagen. 51, 156-163.
8. Croy, R. G., and Wogan, G. N. (1981). Temporal patterns of covalent DNA adducts in rat liver after single and multiple doses of aflatoxin B1. Cancer Res. 41, 197-203.
9. Eaton, D. L., and Gallagher, E. P. (1994). Mechanisms of aflatoxin carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 34, 135-172.
10. Egner, P. A., Groopman, J. D., Wang, J. S., Kensler, T. W., and Friesen, M. D. (2006). Quantification of aflatoxin-B1-N7-guanine in human urine by highperformance liquid chromatography and isotope dilution tandem mass spectrometry. Chem. Res. Toxicol. 19, 1191-1195.
11. Foster, P. L., Eisenstadt, E., and Miller, J. H. (1983). Base substitution mutations induced by metabolically activated aflatoxin B1. Proc. Natl. Acad. Sci. U.S.A. 80, 2695-2698.
12. Groopman, J. D., Busby, W. F., Jr., and Wogan, G. N. (1980). Nuclear distribution of aflatoxin B1 and its interaction with histones in rat liver in vivo. Cancer Res. 40, 4343-4351.
13. Groopman, J. D., Croy, R. G., and Wogan, G. N. (1981). In vitro reactions of aflatoxin B1-adducted DNA. Proc. Natl. Acad. Sci. U.S.A. 78, 5445-5449.
14. Groopman, J. D., Jackson, P. E., Turner, P., Wild, C. P., and Kensler, T. W. (2002). Validation of exposure and risk biomarkers: aflatoxin as a case study. In: Progress in Nucleic Acid Research and Molecular Biology, pp. 307-318. CRC Press, Boca Raton, FL.
15. Groopman, J. D., Kensler, T. W., and Wild, C. P. (2008). Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. Annu. Rev. Public Health 29, 187-203.
16. Hayes, J. D., Judah, D. J., Neal, G. E., and Nguyen, T. (1992). Molecular cloning and heterologous expression of a cDNA encoding a mouse glutathione S-transferase Yc subunit possessing high catalytic activity for aflatoxin B1-8,9-epoxide. Biochem. J. 285(Pt 1), 173-180.
17. Hussain, S. P., Schwank, J., Staib, F., Wang, X. W., and Harris, C. C. (2007). TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26, 2166-2176.
18. Kensler, T. W., Chen, J. G., Egner, P. A., Fahey, J. W., Jacobson, L. P., Stephenson, K. K., Ye, L., Coady, J. L., Wang, J. B., Wu, Y., et al. (2005). Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 14(Pt 1), 2605-2613.
19. Kensler, T. W., Egner, P. A., Davidson, N. E., Roebuck, B. D., Pikul, A., and Groopman, J. D. (1986). Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res. 46, 3924-3931.
20. Masumura, K., Matsui, K., Yamada, M., Horiguchi, M., Ishida, K., Watanabe, M., Ueda, O., Suzuki, H., Kanke, Y., Tindall, K. R., et al. (1999). Mutagenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the new gpt delta transgenic mouse. Cancer Lett. 143, 241-244.
21. Masumura, K., Matsui, K., Yamada, M., Horiguchi, M., Ishida, K., Watanabe, M., Wakabayashi, K., and Nohmi, T. (2000). Characterization of mutations induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the colon of gpt delta transgenic mouse: novel G: C deletions beside runs of identical bases. Carcinogenesis 21, 2049-2056.
22. Nakatani, T., Roy, G., Fujimoto, N., Asahara, T., and Ito, A. (2001). Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Jpn. J. Cancer Res. 92, 249-256.
23. Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., and Karin, M. (2007). Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317(5834), 121-124.
24. Nohmi, T., Katoh, M., Suzuki, H., Matsui, M., Yamada, M., Watanabe, M., Suzuki, M., Horiya, N., Ueda, O., Shibuya, T., et al. (1996). A new transgenic mouse mutagenesis test system using Spi- and 6-thioguanine selections. Environ. Mol. Mutagen. 28, 465-470.
25. Rice, J. M. (1981). Prenatal susceptibility to carcinogenesis by xenobiotic substances including vinyl chloride. Environ. Health Perspect. 41, 179-188.
26. Roebuck, B. D., Curphey, T. J., Li, Y., Baumgartner, K. J., Bodreddigari, S., Yan, J., Gange, S. J., Kensler, T. W., and Sutter, T. R. (2003). Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz. Carcinogenesis 24, 1919-1928.
27. Shupe, T., and Sell, S. (2004). Low hepatic glutathione S-transferase and increased hepatic DNA adduction contribute to increased tumorigenicity of aflatoxin B1 in newborn and partially hepatectomized mice. Toxicol. Lett. 148, 1-9.
28. Smela, M. E., Hamm, M. L., Henderson, P. T., Harris, C. M., Harris, T. M., and Essigmann, J. M. (2002). The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A. 99, 6655-6660.
29. Sun, B., and Karin, M. (2008). NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 27, 6228-6244.
30. Thilly, W. G., Deluca, J. G., Hoppe, H., and Penman, B. W. (1978). Phenotypic lag and mutation to 6-thioguanine resistance in diploid human lymphoblasts. Mutat. Res. 50, 137-144.
31. Thybaud, V., Dean, S., Nohmi, T., de, B. J., Douglas, G. R., Glickman, B. W., Gorelick, N. J., Heddle, J. A., Heflich, R. H., Lambert, I., et al. (2003). In vivo transgenic mutation assays. Mutat. Res. 540, 141-151.
32. Vesselinovitch, S. D. (1990). Perinatal mouse liver carcinogenesis as a sensitive carcinogenesis model and the role of the sex hormonal environment in tumor development. Prog. Clin. Biol. Res. 331, 53-68.
33. Vesselinovitch, S. D., Mihailovich, N., Wogan, G. N., Lombard, L. S., and Rao, K. V. (1972). Aflatoxin B 1, a hepatocarcinogen in the infant mouse. Cancer Res. 32, 2289-2291.
34. Vos, S., Parry, R. J., Burns, M. R., de, J. J., and Martin, J. L. (1998). Structures of free and complexed forms of Escherichia coli xanthine-guanine phosphoribosyltransferase. J. Mol. Biol. 282, 875-889.
35. Wild, C. P., and Montesano, R. (2009). A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett. 286, 22-28.